Next Article in Journal
Evolution of Approaches to the Development, Life Cycle Control, and Interchangeability of Veterinary Biosimilars Based on Hemoproteins (with a Focus on Cytochrome C)
Previous Article in Journal
Salmonellosis as a One Health–One Biofilm Challenge: Biofilm Formation by Salmonella and Alternative Eradication Strategies in the Post-Antibiotic Era
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceuticals
Volume 19
Issue 1
10.3390/ph19010062
pharmaceuticals-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Retraction of Pharmaceuticals 2024, 17(4), 527.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Retraction

RETRACTED: El-Masry et al. Potential Antitumor Activity of Combined Lycopene and Sorafenib Against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024, 17, 527

by
Thanaa A. El-Masry
1,*,†,
Maysa M. F. El-Nagar
1,*,†,
Nageh A. El Mahdy
1,
Fatemah A. Alherz
2,
Reham Taher
1 and
Enass Y. Osman
1
1
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt
2
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Pharmaceuticals 2026, 19(1), 62; https://doi.org/10.3390/ph19010062
Submission received: 4 December 2025 / Accepted: 23 December 2025 / Published: 29 December 2025
(This article belongs to the Section Pharmacology)
Versions Notes
The journal retracts the article “Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation” [1] cited above.
Following publication, concerns were brought to the attention of the Editorial Office regarding the integrity of a number of images presented in this publication [1].
Adhering to our standard procedure, an investigation was conducted by the Editorial Office and Editorial Board that identified irregularities and partial duplication in Figures 2–4 presented in this article. While the authors collaborated with this process, full raw material meeting the journal’s requirements for original images (https://www.mdpi.com/journal/pharmaceuticals/instructions#oriimages, accessed on 3 December 2025) could not be provided for evaluation by the Editorial Board. Consequently, the Editorial Board has lost confidence in the reliability of the findings and has decided to retract this publication, as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30, accessed on 3 December 2025).
This retraction was approved by the Editor-in-Chief of the journal Pharmaceuticals.
The authors disagreed to this retraction.

Reference

  1. El-Masry, T.A.; El-Nagar, M.M.F.; El Mahdy, N.A.; Alherz, F.A.; Taher, R.; Osman, E.Y. RETRACTED: Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024, 17, 527. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

El-Masry, T.A.; El-Nagar, M.M.F.; El Mahdy, N.A.; Alherz, F.A.; Taher, R.; Osman, E.Y. RETRACTED: El-Masry et al. Potential Antitumor Activity of Combined Lycopene and Sorafenib Against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024, 17, 527. Pharmaceuticals 2026, 19, 62. https://doi.org/10.3390/ph19010062

AMA Style

El-Masry TA, El-Nagar MMF, El Mahdy NA, Alherz FA, Taher R, Osman EY. RETRACTED: El-Masry et al. Potential Antitumor Activity of Combined Lycopene and Sorafenib Against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024, 17, 527. Pharmaceuticals. 2026; 19(1):62. https://doi.org/10.3390/ph19010062

Chicago/Turabian Style

El-Masry, Thanaa A., Maysa M. F. El-Nagar, Nageh A. El Mahdy, Fatemah A. Alherz, Reham Taher, and Enass Y. Osman. 2026. "RETRACTED: El-Masry et al. Potential Antitumor Activity of Combined Lycopene and Sorafenib Against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024, 17, 527" Pharmaceuticals 19, no. 1: 62. https://doi.org/10.3390/ph19010062

APA Style

El-Masry, T. A., El-Nagar, M. M. F., El Mahdy, N. A., Alherz, F. A., Taher, R., & Osman, E. Y. (2026). RETRACTED: El-Masry et al. Potential Antitumor Activity of Combined Lycopene and Sorafenib Against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation. Pharmaceuticals 2024, 17, 527. Pharmaceuticals, 19(1), 62. https://doi.org/10.3390/ph19010062

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop